Generic placeholder image

Current Pharmaceutical Biotechnology

Author(s): Marcin Oplawski*, Konrad Dziobek, Nikola Zmarzły, Beniamin O. Grabarek, Robert Kiełbasiński, Przemysław Kieszkowski, Piotr Januszyk, Karol Talkowski, Michał Schweizer, Piotr Kras, Andrzej Plewka and Dariusz Boroń

DOI: 10.2174/1389201020666190918104105

DownloadDownload PDF Flyer Cite As
Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer

Page: [52 - 59] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Many experimental studies have demonstrated the importance of COX-2 in the tumor angiogenesis. Inducible iNOS is responsible for a high and stable level of nitric oxide and is expressed in response to pro-inflammatory factors.

Objective: The aim of this study was to evaluate the expression of COX-2 and iNOS at the protein level and to assess their potential prognostic significance in patients with endometrial cancer.

Methods: The study group consisted of 45 women with endometrial cancer divided according to the degree of histological differentiation i.e. G1, 17; G2, 15; G3, 13. The control group consisted of 15 women without neoplastic changes. The expression of studied proteins was determined immunohistochemically with specific polyclonal antibodies.

Results: Analysis of the COX-2 expression showed that the optical density of the reaction product in G1 reached 186% in the control group, while the values in G2 and G3 reached 243% and 293%, respectively. In the case of iNOS, the optical density of the reaction product reached the following percentages in the control group: 147% in G1, 243% in G2, and 241% in G3.

Conclusion: Our findings suggest that changes in the expression of COX-2 and iNOS may be potentially useful in predicting the progression of endometrial cancer and treatment effectiveness.

Keywords: Endometrial cancer, angiogenesis, COX-2, iNOS, neoplastic changes, molecular marker.

Graphical Abstract

[1]
Gadducci, A.; Sergiampietri, C.; Guiggi, I. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: A novel treatment option. Gynecol. Endocrinol., 2013, 29(9), 811-816.
[http://dx.doi.org/10.3109/09513590.2013.801446] [PMID: 23767831]
[2]
Sinicrope, F.A.; Gill, S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev., 2004, 23(1-2), 63-75.
[http://dx.doi.org/10.1023/A:1025863029529] [PMID: 15000150]
[3]
Shtivelband, M.I.; Juneja, H.S.; Lee, S.; Wu, K.K. Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: Correlation with suppression of cyclooxygenase-2 expression. J. Thromb. Haemost., 2003, 1(10), 2225-2233.
[http://dx.doi.org/10.1046/j.1538-7836.2003.00446.x] [PMID: 14521608]
[4]
Pereg, D.; Lishner, M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J. Intern. Med., 2005, 258(2), 115-123.
[http://dx.doi.org/10.1111/j.1365-2796.2005.01519.x] [PMID: 16018788]
[5]
Turini, M.E.; DuBois, R.N. Cyclooxygenase-2: A therapeutic target. Annu. Rev. Med., 2002, 53, 35-57.
[http://dx.doi.org/10.1146/annurev.med.53.082901.103952] [PMID: 11818462]
[6]
Ogino, S.; Kirkner, G.J.; Nosho, K.; Irahara, N.; Kure, S.; Shima, K.; Hazra, A.; Chan, A.T.; Dehari, R.; Giovannucci, E.L.; Fuchs, C.S. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin. Cancer Res., 2008, 14(24), 8221-8227.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1841] [PMID: 19088039]
[7]
Denkert, C.; Winzer, K.J.; Hauptmann, S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin. Breast Cancer, 2004, 4(6), 428-433.
[http://dx.doi.org/10.3816/CBC.2004.n.006] [PMID: 15023244]
[8]
Liao, Z.; Mason, K.A.; Milas, L. Cyclo-oxygenase-2 and its inhibition in cancer: Is there a role? Drugs, 2007, 67(6), 821-845.
[http://dx.doi.org/10.2165/00003495-200767060-00001] [PMID: 17428102]
[9]
Gasparini, G.; Longo, R.; Sarmiento, R.; Morabito, A. Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol., 2003, 4(10), 605-615.
[http://dx.doi.org/10.1016/S1470-2045(03)01220-8] [PMID: 14554238]
[10]
Ohno, S.; Ohno, Y.; Suzuki, N.; Inagawa, H.; Kohchi, C.; Soma, G.; Inoue, M. Multiple roles of cyclooxygenase-2 in endometrial cancer. Anticancer Res., 2005, 25(6A), 3679-3687.
[PMID: 16302726]
[11]
Qin, W.S.; Deng, Y.H.; Cui, F.C. Sulforaphane protects against acrolein-induced oxidative stress and inflammatory responses: modulation of Nrf-2 and COX-2 expression. Arch. Med. Sci., 2016, 12(4), 871-880.
[http://dx.doi.org/10.5114/aoms.2016.59919] [PMID: 27478470]
[12]
Xu, W.; Liu, L.Z.; Loizidou, M.; Ahmed, M.; Charles, I.G. The role of nitric oxide in cancer. Cell Res., 2002, 12(5-6), 311-320.
[http://dx.doi.org/10.1038/sj.cr.7290133] [PMID: 12528889]
[13]
Shang, Z.J.; Li, J.R. Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: Its correlation with angiogenesis and disease progression. J. Oral Pathol. Med., 2005, 34(3), 134-139.
[http://dx.doi.org/10.1111/j.1600-0714.2004.00259.x] [PMID: 15689226]
[14]
Naseem, K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med., 2005, 26(1-2), 33-65.
[http://dx.doi.org/10.1016/j.mam.2004.09.003] [PMID: 15722114]
[15]
Oka, K.; Suzuki, Y.; Iida, H.; Nakano, T. Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57(1), 217-221.
[http://dx.doi.org/10.1016/S0360-3016(03)00436-X] [PMID: 12909236]
[16]
Choi, B.M.; Pae, H.O.; Jang, S.I.; Kim, Y.M.; Chung, H.T. Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J. Biochem. Mol. Biol., 2002, 35(1), 116-126.
[PMID: 16248976]
[17]
Bulut, A.S.; Erden, E.; Sak, S.D.; Doruk, H.; Kursun, N.; Dincol, D. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: An immunohistochemical study of 151 cases. Virchows Arch., 2005, 447(1), 24-30.
[http://dx.doi.org/10.1007/s00428-005-1250-2] [PMID: 15947943]
[18]
Zafirellis, K.; Zachaki, A.; Agrogiannis, G.; Gravani, K. Inducible nitric oxide synthase expression and its prognostic significance in colorectal cancer. APMIS, 2010, 118(2), 115-124.
[http://dx.doi.org/10.1111/j.1600-0463.2009.02569.x] [PMID: 20132175]
[19]
Yoshida, A.; Sarian, L.O.; Andrade, L.A.; Pignataro, F.; Pinto, G.A.; Derchain, S.F. Cell proliferation activity unrelated to COX-2 expression in ovarian tumors. Int. J. Gynecol. Cancer, 2007, 17(3), 607-614.
[http://dx.doi.org/10.1111/j.1525-1438.2007.00838.x] [PMID: 17504375]
[20]
Sivanesaratnam, V.; Third, S.S.; Third, S.S. Ratnam memorial lecture 2007. Ovarian cancer: Is there hope for women? J. Obstet. Gynaecol. Res., 2009, 35(3), 393-404.
[http://dx.doi.org/10.1111/j.1447-0756.2009.01049.x] [PMID: 19527374]
[21]
Lala, P.K.; Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol., 2001, 2(3), 149-156.
[http://dx.doi.org/10.1016/S1470-2045(00)00256-4] [PMID: 11902565]
[22]
Tarr, J.M.; Eggleton, P.; Winyard, P.G. Nitric oxide and the regulation of apoptosis in tumour cells. Curr. Pharm. Des., 2006, 12(34), 4445-4468.
[http://dx.doi.org/10.2174/138161206779010477] [PMID: 17168753]
[23]
Shi, Q.; Xiong, Q.; Wang, B.; Le, X.; Khan, N.A.; Xie, K. Influence of nitric oxide synthase II gene disruption on tumor growth and metastasis. Cancer Res., 2000, 60(10), 2579-2583.
[PMID: 10825124]
[24]
Klimp, A.H.; Hollema, H.; Kempinga, C.; van der Zee, A.G.; de Vries, E.G.; Daemen, T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res., 2001, 61(19), 7305-7309.
[PMID: 11585770]
[25]
Lechner, M.; Lirk, P.; Rieder, J. Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the same coin. Semin. Cancer Biol., 2005, 15(4), 277-289.
[http://dx.doi.org/10.1016/j.semcancer.2005.04.004] [PMID: 15914026]
[26]
Masunaga, R.; Kohno, H.; Dhar, D.K.; Ohno, S.; Shibakita, M.; Kinugasa, S.; Yoshimura, H.; Tachibana, M.; Kubota, H.; Nagasue, N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res., 2000, 6(10), 4064-4068.
[PMID: 11051257]
[27]
Tamura, M.; Sebastian, S.; Gurates, B.; Yang, S.; Fang, Z.; Bulun, S.E. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J. Clin. Endocrinol. Metab., 2002, 87(7), 3504-3507.
[http://dx.doi.org/10.1210/jcem.87.7.8796] [PMID: 12107271]
[28]
Rao, M.; Yang, W.; Seifalian, A.M.; Winslet, M.C. Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer. Int. J. Colorectal Dis., 2004, 19(1), 1-11.
[http://dx.doi.org/10.1007/s00384-003-0511-2] [PMID: 12783255]
[29]
Ozel, E.; Peştereli, H.E.; Simşek, T.; Erdoğan, G.; Karaveli, F.S. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: Is there any correlation with angiogenesis or clinicopathologic parameters? Int. J. Gynecol. Cancer, 2006, 16(2), 549-555.
[http://dx.doi.org/10.1111/j.1525-1438.2006.00567.x] [PMID: 16681724]
[30]
Prescott, S.M.; Fitzpatrick, F.A. Cyclooxygenase-2 and carcinogenesis. Biochim. Biophys. Acta, 2000, 1470(2), M69-M78.
[PMID: 10722929]
[31]
Szylberg, Ł.; Janiczek, M.; Popiel, A.; Marszałek, A. Expression of COX-2, IL-1β, TNF-α and IL-4 in epithelium of serrated adenoma, adenoma and hyperplastic polyp. Arch. Med. Sci., 2016, 12(1), 172-178.
[http://dx.doi.org/10.5114/aoms.2016.57594] [PMID: 26925134]
[32]
Soumaoro, L.T.; Uetake, H.; Takagi, Y.; Iida, S.; Higuchi, T.; Yasuno, M.; Enomoto, M.; Sugihara, K. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis. Colon Rectum, 2006, 49(3), 392-398.
[http://dx.doi.org/10.1007/s10350-005-0247-x] [PMID: 16474989]
[33]
Lee, J.S.; Choi, Y.D.; Lee, J.H.; Nam, J.H.; Choi, C.; Lee, M.C.; Park, C.S.; Juhng, S.W.; Min, K.W. Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int. J. Gynecol. Cancer, 2006, 16(Suppl. 1), 247-253.
[http://dx.doi.org/10.1136/ijgc-00009577-200602001-00040] [PMID: 16515599]
[34]
Li, M.; Qi, S.Y.; Wang, Y.; Feng, S.X.; Zhang, B.Z.; Wang, R. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors. Arch. Gynecol. Obstet., 2005, 272(1), 48-52.
[http://dx.doi.org/10.1007/s00404-004-0708-9] [PMID: 15682318]
[35]
Fujiwaki, R.; Iida, K.; Kanasaki, H.; Ozaki, T.; Hata, K.; Miyazaki, K. Cyclooxygenase-2 expression in endometrial cancer: Correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum. Pathol., 2002, 33(2), 213-219.
[http://dx.doi.org/10.1053/hupa.2002.31292] [PMID: 11957147]
[36]
Chen, G.; Li, X.; Yang, J.; Li, J.; Wang, X.; He, J.; Huang, Z. Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: A meta-analysis. Arch. Med. Sci., 2016, 12(5), 1110-1117.
[http://dx.doi.org/10.5114/aoms.2016.61916] [PMID: 27695503]
[37]
Nikolic, I.; Andjelkovic, M.; Zaric, M.; Zelen, I.; Canovic, P.; Milosavljevic, Z.; Mitrovic, M. Induction of mitochondrial apoptotic pathway by raloxifene and estrogen in human endometrial stromal ThESC cell line. Arch. Med. Sci., 2017, 13(2), 293-301.
[http://dx.doi.org/10.5114/aoms.2016.59874] [PMID: 28261281]
[38]
Amir, M.; Agarwal, H.K. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie, 2005, 60(8), 563-570.
[PMID: 16124396]
[39]
Gately, S.; Kerbel, R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor Res., 2003, 37, 179-192.
[http://dx.doi.org/10.1159/000071373] [PMID: 12795055]
[40]
Uotila, P.J.; Erkkola, R.U.; Klemi, P.J. The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann. Med., 2002, 34(6), 428-433.
[http://dx.doi.org/10.1080/078538902321012379] [PMID: 12523498]
[41]
Jeon, Y.T.; Kang, S.; Kang, D.H.; Yoo, K.Y.; Park, I.A.; Bang, Y.J.; Kim, J.W.; Park, N.H.; Kang, S.B.; Lee, H.P.; Song, Y.S. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol. Biomarkers Prev., 2004, 13(9), 1538-1542.
[PMID: 15342458]
[42]
Wood, N.J.; Quinton, N.A.; Burdall, S.; Sheridan, E.; Duffy, S.R. Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. Int. J. Gynecol. Cancer, 2007, 17(2), 447-454.
[http://dx.doi.org/10.1111/j.1525-1438.2007.00867.x] [PMID: 17316360]
[43]
Sumitani, K.; Kamijo, R.; Toyoshima, T.; Nakanishi, Y.; Takizawa, K.; Hatori, M.; Nagumo, M. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J. Oral Pathol. Med., 2001, 30(1), 41-47.
[http://dx.doi.org/10.1034/j.1600-0714.2001.300107.x] [PMID: 11140899]
[44]
Cao, Q.J.; Einstein, M.H.; Anderson, P.S.; Runowicz, C.D.; Balan, R.; Jones, J.G. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int. J. Gynecol. Pathol., 2002, 21(2), 147-154.
[http://dx.doi.org/10.1097/00004347-200204000-00007] [PMID: 11917224]
[45]
Hasegawa, K.; Ishikawa, K.; Kawai, S.; Torii, Y.; Kawamura, K.; Kato, R.; Tsukada, K.; Udagawa, Y. Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor. Oncol. Rep., 2013, 30(6), 2937-2944.
[http://dx.doi.org/10.3892/or.2013.2790] [PMID: 24100466]
[46]
Hasegawa, K.; Torii, Y.; Ishii, R.; Oe, S.; Kato, R.; Udagawa, Y. Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch. Gynecol. Obstet., 2011, 284(6), 1515-1521.
[http://dx.doi.org/10.1007/s00404-011-1883-0] [PMID: 21431842]
[47]
Kasap, E.; Karaarslan, S.; Gur, E.B.; Genc, M.; Sahin, N.; Güclü, S. Investigation of the roles of cyclooxygenase-2 and galectin-3 expression in the pathogenesis of premenopausal endometrial polyps. J. Pathol. Transl. Med., 2016, 50(3), 225-230.
[http://dx.doi.org/10.4132/jptm.2016.03.08] [PMID: 27086598]
[48]
Carvalho, F.M.; Aguiar, F.N.; Tomioka, R.; de Oliveira, R.M.; Frantz, N.; Ueno, J. Functional endometrial polyps in infertile asymptomatic patients: A possible evolution of vascular changes secondary to endometritis. Eur. J. Obstet. Gynecol. Reprod. Biol., 2013, 170(1), 152-156.
[http://dx.doi.org/10.1016/j.ejogrb.2013.05.012] [PMID: 23773528]
[49]
Athanassiadou, P.; Grapsa, D.; Athanassiades, P.; Gonidi, M.; Athanassiadou, A.M.; Tsipis, A.; Patsouris, E. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol. Res. Pract., 2008, 204(4), 241-249.
[http://dx.doi.org/10.1016/j.prp.2007.11.004] [PMID: 18171606]
[50]
Seo, S.S.; Song, Y.S.; Kang, D.H.; Park, I.A.; Bang, Y.J.; Kang, S.B.; Lee, H.P. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol. Oncol., 2004, 92(3), 927-935.
[http://dx.doi.org/10.1016/j.ygyno.2003.11.055] [PMID: 14984962]
[51]
Kanty Kulpa, J.; Rychlik, U.; Tarapacz, U.; Rychlik, M.; Stasik, Z.; Wójcik, E.; Kruczak, A.; Koryga-Wszołek, S. Indeks masy ciała (BMI) a stan zapalny u chorych na endometrialnego raka trzonu macicy. J. Lab. Diagnos., 2013, 49, 201-208.
[52]
Munkarah, A.; Ali-Fehmi, R. COX-2: A protein with an active role in gynecological cancers. Curr. Opin. Obstet. Gynecol., 2005, 17(1), 49-53.
[http://dx.doi.org/10.1097/00001703-200502000-00009] [PMID: 15711411]
[53]
Li, W.; Xu, R.J.; Jiang, L.H.; Shi, J.; Long, X.; Fan, B. Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma. Med. Oncol., 2005, 22(1), 63-70.
[http://dx.doi.org/10.1385/MO:22:1:063] [PMID: 15750198]
[54]
Hao, X.P.; Pretlow, T.G.; Rao, J.S.; Pretlow, T.P. Inducible Nitric Oxide Synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res., 2001, 61(2), 419-422.
[PMID: 11212223]
[55]
Malone, J.M.; Saed, G.M.; Diamond, M.P.; Sokol, R.J.; Munkarah, A.R. The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am. J. Obstet. Gynecol., 2006, 194(4), 1110-1116.
[http://dx.doi.org/10.1016/j.ajog.2005.12.019] [PMID: 16580304]
[56]
Tavares Murta, B.M. Cunha, Fde.Q.; Miranda, R.; Adad, S.J.; Murta, E.F. Differential tumor microenvironment in human ovarian cystic tumors. Tumori, 2004, 90(5), 491-497.
[http://dx.doi.org/10.1177/030089160409000509] [PMID: 15656335]
[57]
Sanhueza, C.; Araos, J.; Naranjo, L.; Barros, E.; Subiabre, M.; Toledo, F.; Gutiérrez, J.; Chiarello, D.I.; Pardo, F.; Leiva, A.; Sobrevia, L. Nitric oxide and pH modulation in gynaecological cancer. J. Cell. Mol. Med., 2016, 20(12), 2223-2230.
[http://dx.doi.org/10.1111/jcmm.12921] [PMID: 27469435]
[58]
Bentz, B.G.; Barnes, M.N.; Haines, G.K.; Lurain, J.R.; Hanson, D.G.; Radosevich, J.A. Cytoplasmic localization of endothelial constitutive nitric oxide synthase in endometrial carcinomas. Tumour Biol., 1997, 18(5), 290-300.
[http://dx.doi.org/10.1159/000218042] [PMID: 9276029]
[59]
Oztürk, E.; Dikensoy, E.; Balat, O.; Uğur, M.G.; Balcı, S.O.; Aydın, A.; Kazancı, U.; Pehlivan, S. Association of endothelial nitric oxide synthase gene polymorphisms with endometrial carcinoma: A preliminary study. J. Turk. Ger. Gynecol. Assoc., 2011, 12(4), 229-233.
[http://dx.doi.org/10.5152/jtgga.2011.47] [PMID: 24592000]
[60]
Li, W.; Xu, R.J.; Jiang, L.H.; Shi, J.; Long, X.; Fan, B. Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma. Med. Oncol., 2005, 22(1), 63-70.
[http://dx.doi.org/10.1385/MO:22:1:063] [PMID: 15750198]
[61]
Ferrandina, G.; Legge, F.; Ranelletti, F.O.; Zannoni, G.F.; Maggiano, N.; Evangelisti, A.; Mancuso, S.; Scambia, G.; Lauriola, L. Cyclooxygenase-2 expression in endometrial carcinoma: Correlation with clinicopathologic parameters and clinical outcome. Cancer, 2002, 95(4), 801-807.
[http://dx.doi.org/10.1002/cncr.10736] [PMID: 12209724]
[62]
Jeon, Y.T.; Kang, S.; Kang, D.H.; Yoo, K.Y.; Park, I.A.; Bang, Y.J.; Kim, J.W.; Park, N.H.; Kang, S.B.; Lee, H.P.; Song, Y.S. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol. Biomarkers Prev., 2004, 13(9), 1538-1542.
[PMID: 15342458]
[63]
Li, W.; Xu, R.J.; Jiang, L.H.; Shi, J.; Long, X.; Fan, B. Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma. Med. Oncol., 2005, 22(1), 63-70.
[http://dx.doi.org/10.1385/MO:22:1:063] [PMID: 15750198]
[64]
Ma, X.J.; Wang, Z.; Ryan, P.D.; Isakoff, S.J.; Barmettler, A.; Fuller, A.; Muir, B.; Mohapatra, G.; Salunga, R.; Tuggle, J.T.; Tran, Y.; Tran, D.; Tassin, A.; Amon, P.; Wang, W.; Wang, W.; Enright, E.; Stecker, K.; Estepa-Sabal, E.; Smith, B.; Younger, J.; Balis, U.; Michaelson, J.; Bhan, A.; Habin, K.; Baer, T.M.; Brugge, J.; Haber, D.A.; Erlander, M.G.; Sgroi, D.C. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 2004, 5(6), 607-616.
[http://dx.doi.org/10.1016/j.ccr.2004.05.015] [PMID: 15193263]
[65]
Jansen, M.P.; Sieuwerts, A.M.; Look, M.P.; Ritstier, K.; Meijer-van Gelder, M.E.; van Staveren, I.L.; Klijn, J.G.; Foekens, J.A.; Berns, E.M. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: A retrospective study. J. Clin. Oncol., 2007, 25(6), 662-668.
[http://dx.doi.org/10.1200/JCO.2006.07.3676] [PMID: 17308270]
[66]
Kopczyńska, E.; Dancewicz, M.; Kowalewski, J.; Makarewicz, W.; Kardymowicz, H.; Tyrakowski, T. Usefulness of MMP-9/TIMP-1 ratio in estimation of lung cancer invasion and metastasis. Contemporary Oncology. Contemp. Oncol., 2007, 11, 355-360.
[67]
Roelofs, H.M.; Te Morsche, R.H.; van Heumen, B.W.; Nagengast, F.M.; Peters, W.H. Over-expression of COX-2 mRNA in colorectal cancer. BMC Gastroenterol., 2014, 14, 1.
[http://dx.doi.org/10.1186/1471-230X-14-1] [PMID: 24383454]
[68]
Anttila, M.A.; Voutilainen, K.; Merivalo, S.; Saarikoski, S.; Kosma, V.M. Prognostic significance of iNOS in epithelial ovarian cancer. Gynecol. Oncol., 2007, 105(1), 97-103.
[http://dx.doi.org/10.1016/j.ygyno.2006.10.049] [PMID: 17174383]
[69]
Wcisło-Dziadecka, D.; Grabarek, B.; Zmarzły, N.; Skubis, A.; Sikora, B.; Kruszniewska-Rajs, C.; Gola, J.; Mazurek, U.; Kucharz, E. Influence of adalimumab on the expression profile of genes associated with the histaminergic system in the skin fibroblasts in vitro. BioMed Res. Int., 2018, 2018 1582173
[http://dx.doi.org/10.1155/2018/1582173] [PMID: 29487864]
[70]
Opławski, M.; Michalski, M.; Witek, A.; Michalski, B.; Zmarzły, N.; Jęda-Golonka, A.; Styblińska, M.; Gola, J.; Kasprzyk-Żyszczyńska, M.; Mazurek, U.; Plewka, A. Identification of a gene expression profile associated with the regulation of angiogenesis in endometrial cancer. Mol. Med. Rep., 2017, 16(3), 2547-2555.
[http://dx.doi.org/10.3892/mmr.2017.6868] [PMID: 28656251]
[71]
Xu, W.; Liu, L.; Charles, I.G. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J., 2002, 16(2), 213-215.
[http://dx.doi.org/10.1096/fj.01-0590fje] [PMID: 11772948]